2018
DOI: 10.3899/jrheum.170222
|View full text |Cite
|
Sign up to set email alerts
|

Challenges and Advances in Targeting Remission in Axial Spondyloarthritis

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

1
6
0

Year Published

2019
2019
2022
2022

Publication Types

Select...
7

Relationship

2
5

Authors

Journals

citations
Cited by 11 publications
(7 citation statements)
references
References 39 publications
1
6
0
Order By: Relevance
“…Considering that patients with TNFi treatment for less than 1 year were excluded, the possibility of achieving the target could be lower in real-world settings [20, 21]. The finding is also consistent with the results of previous randomized controlled trials where the probability of achieving ASDAS-ID with TNFi treatment ranged between 16.1 and 36.5% [5, 2224]. In contrast, BASDAI50 criteria were fulfilled in approximately 80% of the intervals, indicating that it is a more lenient target than ASDAS-ID.…”
Section: Discussionsupporting
confidence: 84%
“…Considering that patients with TNFi treatment for less than 1 year were excluded, the possibility of achieving the target could be lower in real-world settings [20, 21]. The finding is also consistent with the results of previous randomized controlled trials where the probability of achieving ASDAS-ID with TNFi treatment ranged between 16.1 and 36.5% [5, 2224]. In contrast, BASDAI50 criteria were fulfilled in approximately 80% of the intervals, indicating that it is a more lenient target than ASDAS-ID.…”
Section: Discussionsupporting
confidence: 84%
“…Although an internal task force has recommended a T2T strategy, with ASDAS as the suggested tool for the management of axSpA [4], a lack of evidence from RCTs for the added value of a T2T strategy in axSpA and the lack of universally accepted remission criteria are major barriers to the implementation of a T2T approach in axSpA [7][8][9]. Recently, ASDAS-ID (score \ 1.3) has been recommended as a preferred measure for remission in AS since it is a composite index with validated cutoffs, including an objective marker of inflammation (C-reactive protein) [4,34].…”
Section: Discussionmentioning
confidence: 99%
“…Shift analysis on ASDAS status from week 16 to 156 included the following ASDAS disease activity states based on validated criteria: very high disease activity (VHDA), [ 3.5; high disease activity 2.1-to 3.5; LDA, 1.3 to \ 2.1; and ID, \ 1.3 [26,33]. Sustainability of ASAS-PR at the individual patient level was assessed between week 16 and weeks 104 and 156 [7]. Shift analysis on BASDAI states from week 16 to 156 was based on following (non-validated) threshold criteria (C 4, C 3 to \ 4, [ 2 to \ 3, and B 2).…”
Section: Statistical Analysesmentioning
confidence: 99%
See 1 more Smart Citation
“… 7 On the other hand, an active discussion of experts is ongoing in both PsA and AxSpA - multifaceted diseases with different manifestations - including the natural course in each individual patient. 2 , 8 Of note, the recent guidelines and recommendations of the American College of Rheumatology, in collaboration with the National Psoriasis Foundation for the Treatment of Psoriatic Arthritis and the Spondylitis Association of America/Spondyloarthritis Research and Treatment Network for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis, indicate a different approach. 9 , 10 The conditional recommendation for PsA is to use a treat-to-target strategy without a clear proposal for a specific index-based target, indicating that a patient-doctor discussion may define it individually.…”
Section: Introductionmentioning
confidence: 99%